Rockefeller Philanthropy Advisors helps donors create thoughtful, effective philanthropy throughout the world. RPA assists individuals, trusts, foundations and corporations in achieving their philanthropy goals and acts as a fiscal sponsor for innovative nonprofit initiatives and funder collaboratives.
Established in 1992 in DE
COVID-19 Early Treatment Fund (CETF)
COVID-19 Early Treatment Fund (CETF) was established by entrepreneur and philanthropist Steve Kirsch to fund outpatient clinical trials on re-purposed drugs, the quickest, safest, and lowest cost way to re-open our world until better drugs are discovered. CETF is managed by Rockefeller Philanthropy Advisors (RPA), a 501(c)(3) charity. The CETF Scientific Advisory Board (SAB) recommends the grants and RPA disburses the funds. The scientific advisory board includes Dr. Robert Siliciano, an immunologist and virologist Johns Hopkins University; Dr. Rich D’Aquila, an infectious disease expert at Northwestern University and Harvard clinical trials expert Dr. Raj Gandhi.